The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care.The new cobas c ...

INDIANAPOLIS, Sept. 19, 2022 /PRNewswire/ -- Roche (RHHBY) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the cobas ® pure integrated solutions, the next ...

Roche Diagnostics announced today that it has introduced a complete battery of STAT immunoassays for cardiac biomarker testing on the cobas 6000 analyzer series, an integrated system designed for ...

Roche has introduced the cobas Respiratory flex test, a new diagnostic that utilises the company's temperature-activated generation of signal (TAGS) technology.

The test represents the final component of the acute panel within the hepatitis test menu for the cobas 6000 series.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its new analytical units, cobas® c 703 and cobas® ISE neo, for the cobas® pro integrated solutions, in countries accepting the CE mark.

Furthermore, to ensure effective and efficient work within healthcare networks, the cobas pure system operates seamlessly with Roche's cobas pro integrated solutions for mid- to high-volume labs.

Furthermore, to ensure effective and efficient work within healthcare networks, the cobas pure system operates seamlessly with Roche's cobas pro integrated solutions for mid- to high-volume labs.